China Hypertension Alliance Grass-roots Council set up a peak set up "hypertension community prevention and control training fund"
Release time:
2020-07-22
China Hypertension Alliance Basic Level Council Established
Peak Established "Hypertension Community Prevention Training Fund "
News 10 17-20 , 2019 China Hypertension Annual Conference and 21 International Hypertension and Related Diseases Symposium Held in Xiamen, during this period, the grass-roots council of the China Hypertension Alliance was established. Jianfeng Group invested ,100 yuan to set up "Hypertension Community Prevention and Control Training Fund " for relevant training and study of grass-roots doctors.
China Hypertension Alliance is the only member of the World Hypertension Alliance (WHL ) in China. It has been committed to publicizing hypertension knowledge, carrying out prevention and treatment of hypertension diseases, and carrying out relevant academic exchanges and scientific research at home and abroad. According to statistics, at present, the incidence rate of hypertension among the population aged , 18 and 32 in China is , 27.9, , and the population suffering from hypertension is , 2.45 .6 billion. However, the awareness rate, treatment rate and control rate of patients are still very low, which has become a difficult problem for the whole society, therefore, the "Healthy China 2030 Planning Outline" specifically proposes to strive to increase the awareness rate, treatment rate and control rate of hypertension to 70% , 99% and 50% respectively by 2030 . To this end, the China Hypertension League established a secondary branch "China Hypertension League Grassroots Council " , dedicated to the prevention and management of hypertension at the grassroots level. To support this work, Jianfeng Group funded the establishment of "Hypertension Community Prevention Training Fund " . Jiang Xiaomeng, chairman of
Group Company and chairman of Jianfeng Pharmaceutical Co., Ltd., said in his speech at the ceremony that Jianfeng Pharmaceutical Co., Ltd. has always made unremitting efforts in the community hypertension prevention and training fund in line with the enterprise spirit of "to set up a high-quality medicine " , and has always taken the promotion of people's health as its own responsibility. The establishment of "community hypertension prevention and treatment training fund " aims to carry out multi-level and wide coverage of basic hypertension standardized diagnosis and treatment training, long-term management of grass-roots hypertension and other topics of training and continuing education, and make efforts to improve the hypertension management level of grass-roots health and medical institutions and grass-roots doctors.
is the mainstream antihypertensive drug in the current Chinese market. Jianfeng Pharmaceutical's CCB class antihypertensive drug aspartate amlodipine tablets (Leisid) has attracted widespread attention and won unanimous praise from the experts attending the meeting due to its unique effects of double-effect integration and smooth antihypertensive effect. (Zhou Wenyi Fang Wentong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page